Compugen Company Profile (NASDAQ:CGEN)

About Compugen (NASDAQ:CGEN)

Compugen logoCompugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CGEN
  • CUSIP: N/A
  • Web:
  • Market Cap: $199.41 million
  • Outstanding Shares: 51,131,000
Average Prices:
  • 50 Day Moving Avg: $3.61
  • 200 Day Moving Avg: $3.81
  • 52 Week Range: $2.60 - $6.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.57
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $123,000.00
  • Price / Sales: 1,558.87
  • Book Value: $0.92 per share
  • Price / Book: 4.08
  • EBITDA: ($33,140,000.00)
  • Return on Equity: -57.69%
  • Return on Assets: -50.83%
  • Current Ratio: 9.40%
  • Quick Ratio: 9.40%
  • Average Volume: 120,777 shs.
  • Beta: 0.68
  • Short Ratio: 13.46

Frequently Asked Questions for Compugen (NASDAQ:CGEN)

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) issued its earnings results on Wednesday, August, 2nd. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. View Compugen's Earnings History.

When will Compugen make its next earnings announcement?

Compugen is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Compugen.

Where is Compugen's stock going? Where will Compugen's stock price be in 2017?

1 analysts have issued 1-year price objectives for Compugen's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Compugen's stock price to reach $14.00 in the next twelve months. View Analyst Ratings for Compugen.

What are analysts saying about Compugen stock?

Here are some recent quotes from research analysts about Compugen stock:

  • 1. According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (10/3/2017)
  • 2. FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:

  • Martin S. Gerstel, Chairman of the Board
  • Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director
  • Ari Krashin, Chief Financial Officer
  • Zurit Levine Ph.D., Vice President - Research and Discovery
  • John Hunter, Vice President - Antibody Research & Development
  • Dov Hershberg, Director
  • Michal Preminger Ph.D., Director
  • Yair Aharonowitz Ph.D., Independent External Director
  • Ruth Arnon, Independent Director
  • Arie Ovadia, Independent External Director

How do I buy Compugen stock?

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of Compugen stock can currently be purchased for approximately $3.75.

MarketBeat Community Rating for Compugen (NASDAQ CGEN)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  255
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Compugen (NASDAQ:CGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (273.33% upside)
Consensus Price Target History for Compugen (NASDAQ:CGEN)
Price Target History for Compugen (NASDAQ:CGEN)
Analysts' Ratings History for Compugen (NASDAQ:CGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017FBR & CoSet Price TargetBuy$14.00HighView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
2/11/2016Jefferies Group LLCReiterated RatingBuy$11.00 -> $9.00N/AView Rating Details
2/1/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Compugen (NASDAQ:CGEN)
Earnings by Quarter for Compugen (NASDAQ:CGEN)
Earnings History by Quarter for Compugen (NASDAQ CGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/20176/30/2017($0.17)($0.18)$0.21 millionViewListenView Earnings Details
5/9/20173/31/2017($0.18)($0.17)$0.06 millionViewListenView Earnings Details
2/15/2017Q416($0.18)($0.17)$0.13 million$0.05 millionViewListenView Earnings Details
11/7/2016Q316($0.14)($0.15)$0.41 million$0.07 millionViewN/AView Earnings Details
8/2/2016Q116($0.17)($0.13)$0.11 million$0.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.16)($0.17)$0.12 million$0.09 millionViewListenView Earnings Details
2/9/2016Q415($0.11)($0.01)$3.33 million$8.30 millionViewN/AView Earnings Details
11/3/2015Q315($0.15)($0.13)$0.92 million$0.23 millionViewN/AView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.58 million$0.22 millionViewN/AView Earnings Details
5/5/2015Q115($0.13)($0.12)$1.88 million$0.51 millionViewN/AView Earnings Details
2/10/2015Q414($0.08)($0.03)$3.70 million$6.60 millionViewN/AView Earnings Details
10/29/2014Q314($0.11)($0.11)$1.90 million$1.70 millionViewN/AView Earnings Details
8/6/2014Q214($0.10)($0.07)$1.85 million$2.00 millionViewN/AView Earnings Details
5/19/2014Q114($0.11)($0.04)$0.16 million$2.10 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)$0.13 million$1.80 millionViewN/AView Earnings Details
10/29/2013Q313($0.12)$0.11 million$1.60 millionViewN/AView Earnings Details
11/5/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Compugen (NASDAQ:CGEN)
2017 EPS Consensus Estimate: ($0.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.17)($0.18)
Q2 20172($0.17)($0.17)($0.17)
Q3 20172($0.19)($0.17)($0.18)
Q4 20172($0.18)($0.17)($0.18)
(Data provided by Zacks Investment Research)


Dividend History for Compugen (NASDAQ:CGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Compugen (NASDAQ:CGEN)
No insider trades for this company have been tracked by


Headline Trends for Compugen (NASDAQ:CGEN)
Latest Headlines for Compugen (NASDAQ:CGEN)
DateHeadline logoCompugen's CGEN-15032 shows potential as immuno-suppressive target in research study, shares ahead 8% premarket - Seeking Alpha - October 11 at 6:39 PM logoCorporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032 - October 11 at 6:39 PM logoCompugen (CGEN) Says New Immunomodulatory Target Demonstrates Potential for First-in-Class Cancer Therapy - - October 9 at 5:47 PM logoA New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy - October 9 at 5:47 PM logoFlexion Shares Continue Rise After FDA Approval -- Biotech Movers - October 9 at 5:47 PM logoCompugen Ltd (CGEN): How Does It Impact Your Portfolio? - October 2 at 4:28 PM logoFinancial Review: Incyte Corporation (INCY) versus Compugen (CGEN) - September 16 at 2:30 AM logoCompugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month - August 7 at 5:32 PM logoQ3 2017 EPS Estimates for Compugen Ltd. (NASDAQ:CGEN) Reduced by Jefferies Group - August 4 at 8:30 AM logoCompugen Ltd. (CGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - August 3 at 8:08 PM logoCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board - - August 3 at 6:36 PM logoCompugen's (CGEN) CEO Anat Cohen-Dayag on Q2 2017 Results - Earnings Call Transcript - August 2 at 5:54 PM logoCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board - August 2 at 5:54 PM logoCompugen Reports Second Quarter 2017 Results - August 2 at 5:54 PM logoCompugen Welcomes Paul Sekhri as its New Chairman of the Board - August 2 at 5:54 PM logoCompugen reports 2Q loss - August 2 at 5:54 PM logo Brokerages Expect Compugen Ltd. (CGEN) Will Announce Earnings of -$0.17 Per Share - July 28 at 10:24 PM logoBRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncology - July 28 at 2:38 AM logoCompugen (CGEN) Reprts Updates to Collaborative Activities with Bayer in Immuno-Oncology - July 28 at 2:38 AM logoBUZZ-US STOCKS ON THE MOVE- Boeing, AMD, Akamai, Corning - Nasdaq - July 27 at 9:37 PM logoCompugen Ltd. (CGEN) Set to Announce Quarterly Earnings on Wednesday - July 27 at 9:59 AM logoCompugen (CGEN) Reprts Updates to Collaborative Activities with ... - - July 26 at 5:39 PM logoCompugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology - July 26 at 5:39 PM logoCompugen (CGEN) Receives US Patent for COM701 - - July 25 at 5:07 PM logoCompugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate - July 25 at 5:06 PM logoCompugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET - July 24 at 11:40 AM logo$210,000.00 in Sales Expected for Compugen Ltd. (CGEN) This Quarter - July 6 at 10:04 AM logoCompugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.17 Per Share - July 4 at 6:20 PM logoCompugen (CGEN) Reports COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models at ... - - June 6 at 4:27 PM logoCompugen provides update on COM701 and upcoming ... - Seeking Alpha - May 31 at 9:31 PM logoCompugen (CGEN) Appoints Michal Preminger to Board of Directors - - May 25 at 5:43 PM logoCompugen (CGEN) Appoints Michal Preminger to Board of Directors - - May 25 at 5:43 PM logoCompugen Reports First Quarter 2017 Results - PR Newswire (press release) - May 10 at 8:25 AM logoCompugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO - PR Newswire (press release) - May 6 at 6:40 AM logoBRIEF-Compugen ltd selects of com902 as lead clinical antibody candidate for immuno-oncology program - March 28 at 9:03 PM logoForm 6-K COMPUGEN LTD For: Mar 28 - - March 28 at 12:46 PM logoCompugen (CGEN) Announces Presentations of Summary Results of COM701 at AACR - - March 3 at 4:15 PM logoCompugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery ... - PR Newswire (press release) - March 2 at 7:12 AM logoCompugen Reports Fourth Quarter and Calendar Year 2016 Results - February 16 at 9:30 AM logoFNY Managed Accounts LLC Buys Tesla, St Jude Medical, SPDR S&P 500, Sells LinkedIn, NXP ... - February 9 at 9:38 PM logoCompugen (CGEN) Says CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity - January 4 at 5:18 PM logoBRIEF-Compugen says disclosed animal model results demonstrating restoration of immune tolerance by cgen-15001 - January 4 at 5:18 PM logoCompugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity - January 4 at 5:18 PM logoWhat Makes Compugen Ltd. (CGEN) a Strong Sell? - Nasdaq - December 22 at 4:24 PM logoCompugen Announces Key Highlights from R&D Day - PR Newswire - PR Newswire (press release) - December 8 at 5:03 PM logoCompugen Discloses its Cancer Immunotherapy Program Targeting ... - PR Newswire (press release) - December 8 at 5:03 PM logoCompugen announces key highlights from R&D day - Seeking Alpha - Seeking Alpha - December 8 at 5:03 PM logoCompugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint - December 7 at 4:54 PM logo7:26 am Compugen discusses data demonstrating that the CGEN-15029/PVRIG immune checkpoint represents a new inhibitory component of the known TIGIT axis at recent SITC Annual Meeting - December 7 at 4:54 PM



Compugen (CGEN) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.